Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555814 | 0.81 | CYP3A4 (0.48) | CYP3A4HPGDALDH1A1BACE1PDK2 | |
| SCHEMBL3559875 | 0.80 | MAOB (0.46) | CYP3A4MEN1KMT2AHPGDCA12 | |
| SCHEMBL3562173 | 0.75 | CA2 (0.39) | CYP3A4HPGDCA12ALDH1A1CA1 | |
| SCHEMBL3562013 | 0.75 | CXCR1 (0.42) | MEN1KMT2ACES2CA12ALDH1A1 | |
| SCHEMBL3559775 | 0.72 | CYP3A4 (0.48) | CYP3A4MEN1KMT2ACA12CA1 | |
| SCHEMBL3555765 | 0.71 | CYP3A4 (0.49) | CYP3A4MEN1KMT2AHPGDTDP1 | |
| SCHEMBL5462195 | 0.70 | SELL (0.42) | CYP3A4MEN1KMT2AHPGDCA12 | |
| SCHEMBL5476577 | 0.65 | CYP3A4 (0.52) | CYP3A4MEN1KMT2ACA12ALDH1A1 | |
| SCHEMBL28384045 | 0.65 | TDP1 (0.42) | CYP3A4MEN1KMT2AHPGDCES2 | |
| SCHEMBL7158339 | 0.65 | CYP3A4 (0.40) | CYP3A4MEN1KMT2AHPGDCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662826-B2 | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same | SHIONOGI & CO., LTD. (JP) | 2010-02-16 | — | — | US | disclosed |
| US-20060089362-A1 | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same | SHIONOGI & CO., LTD (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1533308-A2 | A process for producing a simvastatin precursor | Kaneka Corporation (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-6331641-B1 | Process for producing simvastatin | KANEKA CORPORATION (JP) | 2001-12-18 | — | — | US | disclosed |
| EP-1155698-A1 | ORGANOBORON COMPOUNDS EXHIBITING ANTICOCCIDIAL ACTIVITIES | Nitto Kasei Co., Ltd. (JP) | 2001-11-21 | — | — | EP | disclosed |
| EP-1057825-A1 | ISOFLAVANE DERIVATIVES AND IMMUNOPOTENTIATING COMPOSITIONS CONTAINING THE SAME | SHIONOGI & CO., LTD. (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-1055671-A1 | PROCESS FOR PRODUCING SIMVASTATIN | KANEKA CORPORATION (JP) | 2000-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089362-A1 | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same | NADK, PNPO, NQO1 | CYP3A4 300/4885MEN1 3501/4885KMT2A 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.